Effect of hematopoietic stem cell transplantation on meibomian gland structure

被引:0
作者
Novo-Diez, Andrea [1 ]
Horstmann, Jens [2 ,3 ]
Fernandez, Itziar [1 ,2 ,3 ,4 ]
Calonge, Margarita [1 ,2 ,3 ,4 ]
Gonzalez-Garcia, Maria J. [1 ,2 ,3 ,4 ]
Steven, Philipp [2 ,3 ,4 ,5 ]
机构
[1] Univ Valladolid, IOBA Inst Appl Ophthalmobiol, Valladolid, Spain
[2] Univ Cologne, Fac Med, Dept Ophthalmol, Cologne, Germany
[3] Univ Cologne, Univ Hosp Cologne, Cologne, Germany
[4] Biomed Res Networking Ctr Bioengn Biomat & Nanomed, Valladolid, Spain
[5] Univ Cologne, Fac Med, Dept Ophthalmol, Div Dry Eye & Ocular GVHD, Cologne, Germany
关键词
Hematopoietic stem cell transplantation; Conditioning regimen; Meibomian glands; Meibography; Image analysis; VERSUS-HOST-DISEASE; CONSENSUS DEVELOPMENT PROJECT; CLINICAL-TRIALS; DRY EYE; LONGITUDINAL ANALYSIS; OCULAR COMPLICATIONS; MEIBOGRAPHY; DIAGNOSIS; CRITERIA; DYSFUNCTION;
D O I
10.1016/j.jtos.2025.01.014
中图分类号
R77 [眼科学];
学科分类号
100212 ;
摘要
Purpose: To assess morphological changes in the meibomian glands (MGs) pre- and post-hematopoietic stem cell transplantation (HSCT). Methods: Participants yet to undergo HSCT were included in a pre-HSCT group. Meibography images of both lids were graded using Pult's meiboscale and analyzed using a semi-automatic software program. Meibography variables in the pre-HSCT group were compared with those in a control group of healthy participants. The followup group, a subset of the pre-HSCT group, comprised participants followed up for at least 6 months post-HSCT. Ocular Surface Disease Index (OSDI), tear break-up time, corneal fluorescein staining, and Schirmer test were performed. The differences in meibography variables and ocular surface tests pre- and post-HSCT were analyzed. Results: Pre-HSCT and control groups comprised 181 and 24 participants, respectively. The pre-HSCT group had a higher meiboscale in the lower lid (2 vs. 1, p = 0.011) than controls. The follow-up group comprised 20 patients followed up for 12.75 months post-HSCT. After HSCT, the meiboscale of the upper lid was higher (2 vs. 1, p = 0.011), the MG area was lower in both lids (upper lid = 16.14 % vs. 21.49 %, p = 0.001; lower lid = 11.92 % vs. 17.59 %, p = 0.011), and the OSDI increased (15.2 vs. 26.85, p = 0.018) in the second visit compared to the first visit. Conclusions: Alterations in meibography were observed in patients pre- and post-HSCT. This may be attributed to the effect of treatments administered pre-HSCT, although an additive effect of conditioning regimen in the longterm cannot be discarded.
引用
收藏
页码:173 / 180
页数:8
相关论文
共 43 条
  • [21] National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: IIa. The 2020 Clinical Implementation and Early Diagnosis Working Group Report
    Kitko, Carrie L.
    Pidala, Joseph
    Schoemans, Helene M.
    Lawitschka, Anita
    Flowers, Mary E.
    Cowen, Edward W.
    Tkaczyk, Eric
    Farhadfar, Nosha
    Jain, Sandeep
    Steven, Philipp
    Luo, Zhonghui K.
    Ogawa, Yoko
    Stern, Michael
    Yanik, Greg A.
    Cuvelier, Geoffrey D. E.
    Cheng, Guang-Shing
    Holtan, Shernan G.
    Schultz, Kirk R.
    Martin, Paul J.
    Lee, Stephanie J.
    Pavletic, Steven Z.
    Wolff, Daniel
    Paczesny, Sophie
    Blazar, Bruce R.
    Sarantopoulos, Stephanie
    Socie, Gerard
    Greinix, Hildegard
    Cutler, Corey
    [J]. TRANSPLANTATION AND CELLULAR THERAPY, 2021, 27 (07): : 545 - 557
  • [22] Conjunctival subepithelial fibrosis and meibomian gland atrophy in ocular graft-versus-host disease
    Kusne, Yael
    Temkit, M'hamed
    Khera, Nandita
    Patel, Dharmendra R.
    Shen, Joanne F.
    [J]. OCULAR SURFACE, 2017, 15 (04) : 784 - 788
  • [23] TOPICAL CORTICOSTEROID-THERAPY FOR CORNEAL TOXICITY FROM SYSTEMICALLY ADMINISTERED CYTARABINE
    LASS, JH
    LAZARUS, HM
    REED, MD
    HERZIG, RH
    [J]. AMERICAN JOURNAL OF OPHTHALMOLOGY, 1982, 94 (05) : 617 - 621
  • [24] Classification systems for chronic graft-versus-host disease
    Lee, Stephanie J.
    [J]. BLOOD, 2017, 129 (01) : 30 - 37
  • [25] OCULAR COMPLICATIONS OF BONE-MARROW TRANSPLANTATION
    LIVESEY, SJ
    HOLMES, JA
    WHITTAKER, JA
    [J]. EYE, 1989, 3 : 271 - 276
  • [26] Lumley T, 2004, J Stat Software, V9, P1, DOI [10.18637/jss.v009.i08, DOI 10.18637/JSS.V009.I08]
  • [27] Maino, 2000, Clin Eye Vis Care, V12, P113, DOI 10.1016/S0953-4431(00)00053-9
  • [28] Mencucci R, 1997, Eur J Ophthalmol, V7, P13
  • [29] The lack of association between signs and symptoms in patients with dry eye disease
    Nichols, KK
    Nichols, JJ
    Mitchell, GL
    [J]. CORNEA, 2004, 23 (08) : 762 - 770
  • [30] Dry eye after haematopoietic stem cell transplantation
    Ogawa, Y
    Okamoto, S
    Wakui, M
    Watanabe, R
    Yamada, M
    Yoshino, M
    Ono, M
    Yang, HY
    Mashima, Y
    Oguchi, Y
    Ikeda, Y
    Tsubota, K
    [J]. BRITISH JOURNAL OF OPHTHALMOLOGY, 1999, 83 (10) : 1125 - 1130